The Preferential Impairment of Pupil Constriction Stimulated by Blue Light in Patients with Type 2 Diabetes without Autonomic Neuropathy

Table 2

Neurophysiological functions in control subjects and subgroups of type 2 diabetic patients stratified by the severity of neuropathy.

	Control; subjects	Type 2 diabetic patients staged by neuropathy severity
		Stage I	Stage II	Stage III
MCV of median nerve (m/sec)	57.3–59.8	55.6–57.6	54.1–56.1	50.4–53.6
Amplitude of median nerve (mV)	6.68–8.94	5.85–8.74	4.24–5.82	2.82–5.15
SCV of ulnar nerve (m/sec)	62.8–65.1	61.0–63.5	60.1–62.3	57.0–59.7
Amplitude of ulnar nerve (µV)	31.5–41.2	22.3–32.4	20.6–28.2	15.5–22.8
SCV of sural nerve (m/sec)	47.0–49.1	46.5–49.9	46.4–49.3	45.2–48.0^§
Amplitude of sural nerve (µV)	11.5–14.1	9.75–15.1	8.8–11.9	8.5–11.5
Vibration perception threshold (µ/120 c/sec)	1.56–2.64	1.76–3.62	1.91–3.15	2.30–4.00
(%)	3.74–4.45	3.41–4.56	3.51–4.57	2.85–3.98
Warm perception threshold (W/m^2)	−602–−496	−582–−465	−619–−517	−616–−512
Cold perception threshold (W/m^2)	473–588	443–530	509–591	493–586

Data are the 95% confidence intervals in control subjects and the subgroups of the type 2 diabetic patients stratified by the stages of the neuropathy according to the criteria of the Diabetic Neuropathy Study Group in Japan [14]. compared with control subjects, compared with control subjects, compared with patients at stage I neuropathy, and compared with control subjects.
CV: coefficient of variation; MCV: motor nerve conduction velocity; SCV: sensory nerve conduction velocity.